NICOX SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3815 EUR | -0.13% |
|
-0.13% | -11.59% |
| 04-22 | Nicox: cash position of 9.1 million euros at the end of March | CF |
| 02-28 | Nicox, BlackRock Sign Deal for Debt Restructuring | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -11.59% | 20.25M | - | ||
| +7.91% | 72.81B | A | ||
| +12.64% | 9.13B | A- | ||
| -10.56% | 5.13B | A- | ||
| +58.79% | 4.99B | - | ||
| +4.07% | 3.9B | B- | ||
| -16.90% | 2.48B | C- | ||
| -26.13% | 2.32B | - | ||
| +19.31% | 2.17B | - | - | |
| -0.50% | 1.64B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALCOX Stock
- NXOA Stock
- Ratings Nicox SA